SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Snap, Inc. operates as a technology company, which engages in the provision of a visual messaging application that was created to help people communicate through short videos and images. The company was founded by Frank Reginald Brown IV, Evan Thomas Spiegel, and Robert C. Murphy in 2010 and is headquartered in Santa Monica, CA.

Snap Inc - Ordinary Shares - Class A

Snap Inc

Snap's stock is surging as investors react to a Q3 earnings beat, a $500 million stock buyback, and a new $400 million AI partnership with Perplexity. The community is buzzing about the potential for a short squeeze and upgraded price targets, while also weighing concerns about profitability and the long-term sustainability of the rally.

Celsius Holdings, Inc. engages in the development, marketing, sale, and distribution of functional drinks and liquid supplements. It also offers post-workout functional energy drinks and protein bars. The company was founded in April 2004 and is headquartered in Boca Raton, FL.

Celsius Holdings Inc

CELH is trending as investors anticipate upcoming earnings results, with many in the community expecting strong numbers driven by growth and the Alani Nu acquisition. Despite overall market uncertainty, the community expresses long-term confidence in CELH's execution and potential, while also closely monitoring potential short-term volatility and market manipulation.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is trending as investors anticipate Phase 3 data for their DMD treatment, deramiocel, expected mid-Q4, with the community actively discussing potential FDA approval pathways. Discussions also involve the StealthX exosome platform and recent job postings at Capricor and NS Pharma, hinting at possible positive outcomes. Community members are closely monitoring short interest and options activity, speculating on potential market reactions following the data release.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X Shares

Direxion Daily Semiconductor Bull 3X Shares

SOXL is trending as traders assess the semiconductor sector's near-term trajectory amidst AI optimism and US-China trade concerns. Community discussions include reactions to earnings reports from key semiconductor companies and speculation about upcoming economic data releases and Federal Reserve actions. Bullish sentiment persists, while some are wary of overvaluation and the potential for a pullback.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is trending amid speculation about potential partnerships or a buyout, with an earlier earnings call fueling anticipation. Community members are debating the likelihood of a deal, with some eyeing AstraZeneca as a possible partner, while others express skepticism and frustration with management. Bullish sentiment is building as some traders position for a potential breakout and short squeeze ahead of earnings.

Avantis is the largest RWA perps DEX in DeFi, built on and backed by Base. Avantis allows users to trade crypto and real-world assets (RWAs), including FX, commodities, indices, and equities. Backed by Pantera and Coinbase, Avantis is the largest DEX on Base by volumes, and brings institutional-grade products to DeFi, letting users trade with up to 500x leverage in a transparent, permissionless environment.  Avantis is best known for launching zero-fee perpetuals (ZFP) — a first-of-its-kind primitive where traders only pay fees if they profit. They've also brought leveraged RWAs onchain. This has driven explosive growth: over $20B+ in cumulative volume and 15M+ run-rate revenues since Febrruary 2024.

Avantis

Avantis ($AVNT) is trending as community members discuss its tokenomics, specifically the locked dev tokens until February and scheduled buybacks, which some believe will naturally increase the coin price.  Concerns about competitors potentially suppressing the token's price and calls for fair play are also circulating.  Traders are actively watching key price levels and anticipating potential volatility, with some suggesting it's time for a rebound.

$SWEAT is the beating heart of the Movement Economy—a groundbreaking token that transforms physical activity into real-world value. Minted through movement, $SWEAT rewards your steps with a crypto asset that you can earn, trade, or grow. The team states that their app has increased their users’ physical activity by an average of 20%, creating a healthier society and reducing burdens on global healthcare systems. With over 20 million holders, SWEAT is eliminating barriers and making Web3 accessible to everyone, one step at a time.

Sweat Economy

Sweat Economy is trending as the community discusses its potential for future growth and staking opportunities. Many users are accumulating and staking $SWEAT, motivated by the project's concept of earning crypto through walking and its potential for long-term gains. The conversation also highlights anticipation for increased utility and adoption of the Sweat Wallet in the US.

Caledonia Mining Corp. Plc engages in the exploration, development, and production of gold and other precious metals from its mineral properties. Its projects include Blanket Gold Mine and Maligreen. The company was founded on February 5, 1992 and is headquartered in St. Helier, the United Kingdom.

Caledonia Mining Corporation Plc

Caledonia Mining Corporation ($CMCL) is trending due to upcoming earnings and discussions around its potential growth, particularly the Bilboes project which could significantly increase production; the earnings are scheduled to be released Monday before the market opens. Community members are weighing the company's profitability against the political risks of operating in Zimbabwe, with some anticipating a positive impact from rising gold prices and others concerned about potential dilution from financing activities. Recent discussions also touch on the stock's valuation relative to its growth potential and comparison to other gold miners.

Dynavax Technologies Corp. is a biopharmaceutical company, which engages in the provision of discovery, development, and commercialization of novel vaccines and immuno-oncology therapeutics. Its product includes HEPLISAV-B, which prevents infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. The company was founded by Lawrence M. Lichtenstein, Dennis A. Carson, and Eyal Raz on August 29, 1996 and is headquartered in Emeryville, CA.

Dynavax Technologies Corp.

DVAX is trending due to a new $100 million share buyback program and updates regarding a partnership with VXRT for a novel oral COVID-19 vaccine. The community is discussing the potential financial benefits and strategic implications of this agreement, as well as concerns about delays in the FDA study protocol for HLAD in adults on hemodialysis. Investors are also weighing in on the impact of Deep Track's involvement and management's capital allocation decisions.

Duolingo, Inc. is a language-learning website and mobile application, which engages in the development of a free language learning website and crowd sourced text translation platform. It offers Duolingo for Schools, a free, web-based tool that aims to make it easier for teachers to use the Duolingo platform in a structured learning environment, and English Test, an online, on-demand assessment of English proficiency. The company was founded by Luis von Ahn and Severin Hacker in 2011 and is headquartered in Pittsburgh, PA.

Duolingo Inc - Ordinary Shares - Class A

Duolingo Inc

Duolingo is trending amid discussions about its post-earnings drop, despite reporting strong revenue and user growth, as the market reacts to future guidance and broader concerns about growth pace and AI competition. The community is debating whether the dip is an overreaction and a buying opportunity or a sign of deeper issues with the company's valuation and long-term prospects. Some traders are anticipating a potential bounce, while others believe the stock could fall further.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

NovoCure (NVCR) Reports Q3 Loss, Tops Revenue Estimates

NovoCure (NVCR) delivered earnings and revenue surprises of +21.43% and +5.76%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Prime Medicine, Inc. (PRME) Reports Q2 Loss, Lags Revenue Estimates

Prime Medicine, Inc. (PRME) delivered earnings and revenue surprises of -13.89% and -59.60%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Prime Medicine, Inc. (PRME) Now Trades Above Golden Cross: Time to Buy?

Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?

3 Genomics Stocks Worth Adding to Your Portfolio in 2025

CRISPR-based innovators like NTLA, EDIT and PRME are gaining traction as genomics reshapes the future of medicine and biotech

Prime Medicine stock soars amid gene editing sector momentum

Investing.com --  Prime Medicine  (NASDAQ:PRME) stock rose 32%, extending recent gains following Eli Lilly’s (NYSE:LLY) acquisition deal for  Verve Therapeutics  (NASDAQ:VERV) last month. 

Retail chatter for Prime Medicine spiked Monday following Citi's downgrade to 'Neutral' from 'Buy,' with the price target slashed to $1.50 from $10.&nbsp;According to Citi's research note, the shares were trading near cash, reflecting investor uncertainty over the company's path to value inflection.Citi said that Prime Medicine's cash reserves will sustain operations only until mid-2026 despite recent efforts to cut costs and restructure operations.However, management expects initial clinical data will become available for Wilson's Disease and Alpha-1 Antitrypsin Deficiency (AATD) in 2027.Prime Medicine’s shares closed at $1.29 on Friday, up 4.88% or $0.06 for the day.The company said it would restructure by making its Chronic Granulomatous Disease (CGD) programs a lower priority while cutting its workforce by about 25% to concentrate on the liver disease franchise and externally funded programs.The firm maintains progress in its live studies that target two significant genetic liver conditions: Wilson's Disease and Alpha-1 Antitrypsin Deficiency (AATD).It plans to file an investigational new drug (IND) application in the first half of 2026 and mid-2026, respectively. Initial clinical data for these programs are expected in 2027.Prime Medicine also maintains its cystic fibrosis program, which is supported by the Cystic Fibrosis Foundation, and collaborates with Bristol Myers Squibb to develop Prime Edited CAR-T products in hematology, immunology, and oncology.On Stocktwits, retail sentiment was ‘bullish’ amid ‘high’ message volume.One user noted insider buying and a technical double bottom pattern, suggesting the stock could either become a complete write-off or achieve “legendary” success.<stembedurl>https://stocktwits.com/sogenerous/message/615704325</stembedurl>Meanwhile, another user highlighted the company's gene-editing technology and its long-term potential despite the lengthy clinical timelines.<stembedurl>https://stocktwits.com/Shesellsseashells/message/615286716</stembedurl>The stock has declined 57% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Generic picture shows a hand holidng a capsule on 25 July 2004. AFR Picture by LOUIE DOUVIS (Photo by Fairfax Media via Getty Images)

Citi Downgrade Sparks Retail Chatter On Prime Medicine Amid Cash Runway Uncertainty

The biotech firm announced a restructuring to focus on its liver disease programs while cutting costs and workforce amid ongoing development challenges.

Equity

Biotech Stock Roundup: BMRN to Acquire INZY, NVAX Gains on Vaccine Approval & More

Shares of biotechnology company Prime Medicine, Inc. (PRME) fell 18% on Monday afternoon after the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://investors.primemedicine.com/news-releases/news-release-details/prime-medicine-announces-strategic-restructuring-focus">announced</a> a strategic restructuring, including layoffs and the resignation of its CEO in a bid to reduce cash burn.Prime Medicine announced that Keith Gottesdiener will step down as CEO and a member of the company’s board of directors, effective immediately.Allan Reine, Prime Medicine’s Chief Financial Officer (CFO), will now succeed Gottesdiener.The company also announced the deprioritization of its programs aimed at the genetic disorder Chronic Granulomatous Disease (CGD), instead focusing its efforts on the development of programs for genetic liver diseases, Wilson’s Disease, and Alpha-1 Antitrypsin Deficiency (AATD).The company expects to file an investigational new drug (IND) and/or clinical trial application (CTA) for its Wilson’s Disease program in the first half of 2026 and its AATD program in mid-2026. Initial clinical data from both programs is expected the following year.For its CGD program, PM359, the company said it is exploring options for continued clinical development outside the firm.However, the company expressed confidence in the program and believes it has the potential to transform the treatment of the disorder.Prime Medicine also said it is reducing its organizational headcount by approximately 25%.The company believes the multiple initiatives will reduce anticipated cash needs by almost half through 2027.Prime Medicine expects that its cash, cash equivalents, and investments as of March 31, 2025, will be sufficient to fund its operations and capital expenditure requirements into the first half of 2026.On Stocktwits, retail sentiment around PRME rose within the ‘extremely bullish’ territory over the past 24 hours while message volume remained at ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:628/65;" src="https://news.stocktwits-cdn.com/Screenshot_2025_05_19_at_12_06_01_PM_png_ee21a5e357.webp" alt="PRME's Sentiment Meter and Message Volume as of 12:05 p.m. ET on May 19, 2025 | Source: Stocktwits" width="628" height="65"><figcaption>PRME's Sentiment Meter and Message Volume as of 12:05 p.m. ET on May 19, 2025 | Source: Stocktwits</figcaption></figure> <a href="https://stocktwits.com/symbol/PRME">PRME stock</a> is down by about 57% this year and 83% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/protagenic-therapeutics-merges-with-phytanix-bio/ch0cuACRb8E">Protagenic Therapeutics Merges With Phytanix Bio In All-Stock Deal: Retail Turns Extremely Bullish</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Prime Medicine Announces Layoffs, CEO Transition: Retail Gets More Bullish

The company said Keith Gottesdiener will step down as the chief executive, while CFO Allan Reine will succeed him.

Kuehn Law Encourages Investors of Prime Medicine, Inc. to Contact Law Firm

Kuehn Law Encourages Investors of Prime Medicine, Inc. to Contact Law Firm Kuehn Law Encourages Investors of Prime Medicine, Inc. to Contact Law Firm PR Newswire NEW YORK, Jan. 30, 2025 NEW YORK...

Analyst: Sell ‘Magnificent 7’ Stocks and Buy These 3 Dividend Stocks Instead

Analysts at Miramar Capital are advising investors to sell “Magnificent 7” and instead invest in lower-valuation, dividend-paying healthcare stocks.

Prime Medicine, Inc. is a biotechnology company, which engages in developing one-time curative genetic therapies. The company was founded by David R. Liu on September 13, 2019 and is headquartered in Cambridge, MA.

PRME
Prime Medicine Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest PRME News

PRMEPrime Medicine Inc